Features | VJDementia

Aducanumab receives accelerated FDA approval for early Alzheimer’s disease

The Food and Drug Administration (FDA) has granted accelerated approval to aducanumab for the treatment of early Alzheimer’s disease (AD)….

Could retinal changes help predict Alzheimer’s disease onset?

Alzheimer’s disease (AD) is a degenerative condition that affects the brain due to the accumulation of protein aggregates, mainly amyloid…

Medical management issues in dementia: new EAN guideline

The detrimental effects of dementia negatively impact many peoples’ lives – with a markedly decreased quality of life and increased…

Alzheimer’s disease: uncovering the mechanisms of protective mutations

Alzheimer’s disease (AD) is a progressive disease affecting millions worldwide and is well known for its characteristic symptom of memory…

The use of rotigotine as a drug to improve cognitive function in individuals with Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive brain disorder that causes a degeneration of memory and cognitive skills majorly caused by…

A slipped-CAG DNA-binding molecule reverses Huntington’s disease repeat CAG mutation

Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative disease caused by a CAG trinucleotide repeat expansion in the huntingtin…

Vitamin B12 levels could be predictive of Parkinson’s disease dementia

Cognitive impairment, in particular dementia, is one of the most feared non-motor features of Parkinson’s disease (PD).1 Lower levels of…

Plasma pTau181 could differentiate Alzheimer’s disease from other dementias

A recent study published in Nature Medicine has reported advances in the development of a blood test that could help…